SCHEMBL2520179

SCHEMBL2520179

CCCCOc1cccc(OCCCC)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.50
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
GLA P06280 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MCHR1 Q99705 2/20 0.46
HTR7 P34969 1/20 0.46
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
SOAT1 P35610 1/20 0.42
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12093711 0.92 HTR7 (0.45) LTA4HMEN1ALDH1A1LMNAGLA
SCHEMBL8583652 0.91 SOAT1 (0.51) LTA4HTSHRMCHR1HTR7SOAT1
SCHEMBL2521218 0.88 HTR7 (0.47) MEN1ALDH1A1LMNAGLAPOLB
SCHEMBL9440370 0.88 LMNA (0.48) LTA4HMEN1ALDH1A1LMNAGLA
SCHEMBL24306014 0.86 SOAT1 (0.48) LTA4HTSHRMCHR1SOAT1TLR8
SCHEMBL11942197 0.86 KCNH2 (0.44) LTA4HMEN1ALDH1A1LMNAGLA
SCHEMBL7285 0.86 HTR7 (0.65) LTA4HMEN1ALDH1A1LMNAGLA
SCHEMBL10911295 0.86 MCHR1 (0.44) LTA4HMEN1ALDH1A1LMNAGLA
SCHEMBL3133230 0.86 MCHR1 (0.55) MEN1ALDH1A1LMNAGLAPOLB
SCHEMBL24306122 0.85 SOAT1 (0.47) LTA4HTSHRMCHR1HTR7SOAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3251674-A2 ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES BioCryst Pharmaceuticals, Inc. (US) 2017-12-06 EP disclosed
US-20150291596-A1 ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES BIOCRYST PHARMACEUTICALS, INC. 2015-10-15 US disclosed
WO-2014078778-A2 ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES BIOCRYST PHARMACEUTICALS, INC. (US) 2014-05-22 WO disclosed
US-8039552-B2 Process for producing propylene block copolymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-10-18 US disclosed
US-20100036058-A1 PROPYLENE BLOCK COPOLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-02-11 US disclosed
US-20100004395-A1 PROCESS FOR PRODUCING PROPYLENE BLOCK COPOLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-01-07 US disclosed
US-7605215-B2 Process for producing olefin copolymerization catalyst and process for producing olefin copolymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-10-20 US disclosed
US-20080227937-A1 Process for Producing Olefin Copolymerization Catalyst and Process for Producing Olefin Copolymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150291596-A1 ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES RNGTT, DUT, RNMT LTA4H 1723/4885MEN1 4689/4885ALDH1A1 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.